If peptide therapy is appropriate, well outline options and next steps
The tier 3 programme is delivered by a multidisciplinary team including specialist weight management dietitians, physiotherapists, psychologists and obesity physicians over one year [22]
Among the most promising non-incretin receptor targets are amylin (Amy) receptors (AMYRs), supported by data from phase I and phase II clinical trials showing efficacy of the long-acting amylin and calcitonin receptor agonist, cagrilinitide (Cagri), both as monotherapy 2,3 and in combination with the selective GLP-1R agonist, semaglutide 4,5
Both drugs help manage Type 2 diabetes
(2023, May 16)
Gluten degradation, pharmacokinetics, safety, and tolerability of TAK-062, an engineered enzyme to treat celiac disease